Treatment of severe rejection of kidney transplants with Orthoclone OKT3

C. Ponticelli,E. Rivolta,A. Tarantino,A. De Vecchi,G. Banfi,L. Beradinelli,A. Vegeto

DOI: https://doi.org/10.1111/j.1399-0012.1987.tb00698.x

1987-04-01

Clinical Transplantation

Abstract:16 renal transplant recipients developed an acute rejection which, in spite of intravenous high‐dose methylprednisolone, led to an increase in plasma creatinine of at least 8 mg/dl (3 patients) or to need for dialysis (13 patients). The patients were then treated with intravenous monoclonal antibody Orthoclone OKT3. In 13 patients rejection was reversed: 8 of them developed a re‐rejection which was reversed by a further course with methylprednisolone, but I patient had a third rejection and his graft had to be removed. Another patient died from liver failure 27 months later. At present, after a mean follow‐up of 18 ± 10 months, 15 patients (94%) are still alive and 11 patients (69%) have their graft functioning. It is concluded that Orthoclone OKT3 is very effective in reversing severe rejections and can rescue a good proportion of steroid‐resistant transplanted kidneys.

surgery,transplantation